Get the Stockscreener App
1.09
1.80%
-0.02
After Hours:
1.08
-0.01
-0.92%
Hoth Therapeutics Inc stock is traded at $1.09, with a volume of 458.70K.
It is down -1.80% in the last 24 hours and up +1.87% over the past month.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
See More
Previous Close:
$1.11
Open:
$1.13
24h Volume:
458.70K
Relative Volume:
0.06
Market Cap:
$14.33M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.8258
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
+3.81%
1M Performance:
+1.87%
6M Performance:
-0.91%
1Y Performance:
-6.84%
1-Day Range:
$1.0501
$1.185
1-Week Range:
$1.01
$1.185
52-Week Range:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
590 MADISON AVENUE, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.09 | 14.33M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia
Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com
Hoth Dips on Drug Application - Baystreet.ca
Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks
Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India
Hoth Therapeutics to Offer Cancer Treatment HT-001 Under Compassionate Use - StockTitan
Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa
Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India
Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Cancer Patient's Skin Lesions Vanish in Just One Week: Hoth's Experimental Treatment Shows Promise - StockTitan
Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease - Marketscreener.com
Can Hoth's GDNF Protein Disrupt the $70B Obesity Drug Market? Preclinical Results Show Unique Advantage - StockTitan
Financial Contrast: Emmaus Life Sciences (OTCMKTS:EMMA) and Hoth Therapeutics (NASDAQ:HOTH) - Defense World
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN
Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital - Defense World
Hoth Therapeutics to Present at the LD Micro Main Event (XII) - ACCESS Newswire
What to expect from HOTH’s earnings report this quarter? - US Post News
Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic - Contract Pharma
HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research - StockTitan
Hoth Therapeutics expands at-the-market offering by $5 million - Investing.com Australia
Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright - Defense World
Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNew York, NY – January 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced today that it has successfully regained compliance with the minimum bid price requirement s - Defense World
Financial Contrast: Hoth Therapeutics (NASDAQ:HOTH) vs. Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Hoth Therapeutics expands cancer drug patent portfolio - MSN
Hoth Therapeutics Breaks New Ground! Nasdaq Compliance Achieved! - Mi Valle
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements - PR Newswire
Hoth Therapeutics Regains Nasdaq Compliance, Secures Exchange Listing Status - StockTitan
Hoth Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com Australia
Hoth Therapeutics Acquires New Patent Applications - Contract Pharma
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications - PR Newswire
Hoth Therapeutics Expands Cancer Drug Patent Portfolio, Strengthens HT-001 Development Strategy - StockTitan
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Shares Of This Micro Cap More Than Doubled Today - MSN
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Hoth Therapeutics maintains strong cash position, no offering plans By Investing.com - Investing.com Nigeria
Hoth Therapeutics Shares Recover; Company Has No Plans for Offering - MarketWatch
Hoth Therapeutics maintains strong cash position, no offering plans - Investing.com
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):